Effect of Pre-Operative Internal Obturator Muscle Mass Index in MRI on Biochemical Recurrence of Prostate Cancer Patients After Radical Prostatectomy: A Multi-Center Study

Won Tae Kim
Chungbuk National University  https://orcid.org/0000-0002-7482-4550

Ho Won Kang
Chungbuk National University

Sung Pil Seo
Chungbuk National University Hospital

Yong-June Kim
Chungbuk National University

Sang Cheol Lee
Chungbuk National University

Wun-Jae Kim
Chungbuk National University

Bum Sang Cho
Chungbuk National University

Yun Sok Ha
Kyungpook National University

Tae Gyun Kwon
Kyungpook National University

Jinsung Park
Eulji University

Seung Chol Park
Wonkwang University

Young Beom Jeong
Jeonbuk National University

Taek Won Kang
Jeonnam Daehakgyo: Chonnam National University

Sung-Woo Park
Pusan NU: Pusan National University

Seok Joong Yun (sjyun@chungbuk.ac.kr)
Chungbuk National University
Abstract

**Purpose:** Recent reports show that the pre-operative or post-operative skeletal mass index (sarcopenia) affects survival rates for various cancers; however, the link between prostate cancer survival and sarcopenia is unclear. Therefore, this study examined the effect of the pre-operative internal obturator muscle (IOM) mass index on biochemical recurrence (BCR) of prostate cancer (PCa) patients who underwent radical prostatectomy.

**Methods:** In total, 222 patients, who underwent open or robot-assisted radical prostatectomy at seven centers in 2011 and were followed up for 5 years, were enrolled. BCR was examined in the context of pre-operative IOM mass index and BMI.

**Results:** The mean age of the patients was 67.82 ± 6.23 years, and the mean pre-operative prostate-specific antigen (PSA) level was 11.61 ± 13.22 ng/ml. There was no significant difference in baseline characteristics between the low and high IOM mass index groups (p > 0.05). Age, pre-op PSA level, ECE, and T-stage were not associated with BCR (p = 0.049, p < 0.001, p = 0.001, p = 0.004, respectively). BMI, prostate volume, Gleason score, resection margin, N-stage, M-stage and IOM mass index was not associated with BCR (p > 0.05).

**Conclusions:** Pre-operative IOM mass index was not associated with BCR; however, long-term follow-up is necessary to evaluate cancer-specific and overall survival of PCa patients.

Introduction

Prostate cancer (PCa) is the most common cancer in men worldwide.\(^1\) The incidence of PCa in Asia is among the lowest in the world.\(^1\) However, the incidence in the Republic (Rep.) of Korea is increasing rapidly.\(^2\) PCa mortality rates have fallen in high-resource countries, but have increased or remain stable in low-resource countries.\(^1\) PCa-associated mortality in the Rep. of Korea is increasing along with incidence.\(^2\)

Sarcopenia is a condition characterized by progressive and generalized loss of muscle mass and strength.\(^3\) Sarcopenia predicts drug toxicity and time-to-tumor progression in patients undergoing chemotherapy.\(^4\) The impact of sarcopenia in cancer patients has been studied, and data suggest that sarcopenia is independently associated with post-operative outcome following resection of colorectal cancer, hepatocellular carcinoma, pancreatic cancer, and bladder cancer.\(^5^-^8\) In addition, sarcopenia is a prognostic marker for disease recurrence and mortality in patients with urologic cancers.\(^8^-^11\)

Radical prostatectomy (RP) is the gold standard treatment for localized PCa. RP is often the treatment of choice for younger and less morbid patients. A previous report suggests that sarcopenia is associated with non-cancer-related death in PCa patients undergoing radiotherapy.\(^12\) Conversely, Mason et al. report that sarcopenia is not independently associated with perioperative complications or oncologic outcomes.
Therefore, there is a lack of evidence supporting an association between sarcopenia and oncologic outcomes in PCa. Generally, sarcopenia, skeletal mass index (SMI) was defined as the cross-sectional area of the rectus abdominis; internal, external, and transverse obliques; psoas; quadratus lumborum; and erector spinae muscles from L3 down. Most surgeons performed MRI imaging work-up for prostatectomy. So, internal obturator muscle (IOM) is the only measurable muscle in the pelvis MRI axial cut. However, there was no study between pre-operative IOM mass index and oncologic outcomes in PCa. Therefore, we investigated the effect of pre-operative IOM mass index on biochemical recurrence (BCR) in Korean patients after radical RP.

**Material And Methods**

**Study population and data collection**

In total, 222 PCa patients, who underwent open or robot-assisted RP at seven academic centers in 2011 and were followed up for 5 years, were enrolled. All patients had histologically confirmed primary adenocarcinoma of the prostate, and all had undergone pre-operative MRI within 3 months of surgery. Patients were excluded if they had previously received androgen deprivation therapy (ADT) or radiotherapy (RT). In addition, patients undergoing testosterone replacement therapy or taking medications that affect muscle mass were excluded.

Clinical and pathologic data included age, height, body weight, prostate-specific antigen (PSA) levels, prostate volume, pathologic T-, N-, and M-stage, receipt of adjuvant RT or ADT, and follow-up duration. BCR after RP was defined as a post-operative PSA level > 0.2 ng/mL. Patients undergoing adjuvant ADT or RT after RP were excluded in the BCR group. IOM mass index was measured by dividing the mean internal obturator muscle area (calculated from CT or MRI) by height (squared). All internal obturator muscle area measurements were performed by a single radiologist (Cho, BS, Fig. 1). All methods used for sample collection and analyses were approved by the Ethics Committee of Chungbuk National University Hospital, and all subjects provided written informed consent (IRB approval number: 2018-02-021).

**Statistical analysis**

IOM mass index was divided into two groups according to a median cut-off value. BMI was divided to three groups according to Korean BMI criteria. The baseline characteristics of the patients with a low IOM mass index and a high IOM mass index were compared using an independent t-test and the Chi-square test as appropriate. Comparisons of clinical and pathological parameters according to BMI were made using ANOVA and the Chi-square test as appropriate. The association between BCR and pre-operative IOM mass index or BMI values were examined using a Cox proportional hazards model and a Kaplan–Meier survival analysis. Statistical analyses were performed using the Statistical Package for Social Sciences, version 25 software (SPSS, Inc., Chicago, IL, USA). A p-value < 0.05 was considered statistically significant.
Results

Baseline characteristics of the study population according to IOM mass index

The baseline characteristics of all the patients are shown in Table 1. The mean age was 67.82 ± 6.23 years, and the mean pre-operative PSA level was 11.61 ± 13.22 ng/mL. There was no significant difference in baseline characteristics between the low IOM mass index and high IOM mass index groups (p > 0.05).
Table 1
Baseline characteristics of all patients and according to the Internal obturator muscle (IOM) mass Index

| Parameters                  | Overall     | According to the IOM mass index | p-value |
|-----------------------------|-------------|---------------------------------|---------|
|                             |             | Low IOM | High IOM |         |
| Number                      | 222         | 111     | 111      |         |
| Age (years)                 | 67.82 ± 6.23| 68.55 ± 6.11 | 67.10 ± 6.29 | 0.083   |
| IOM (mm$^2$/cm$^2$)         | 11.23 ± 2.22|          |          |         |
| BMI (kg/m$^2$)              | 24.46 ± 2.86| 24.17 ± 2.86 | 24.74 ± 2.85 | 0.136   |
| Pre-op PSA (ng/mL)          | 11.61 ± 13.22 | 11.12 ± 12.29 | 12.11 ± 14.12 | 0.579   |
| Prostate volume (cc)        | 34.58 ± 14.13| 35.56 ± 15.68 | 33.57 ± 12.33 | 0.313   |
| Type of operation           |             |          |          | 0.200   |
| RRP                         | 163 (73.4)  | 77 (69.4) | 86 (77.5) |         |
| LRP                         | 1 (0.5)     | 0        | 1 (0.9)  |         |
| RARP                        | 58 (26.1)   | 34 (30.6) | 24 (21.6) |         |
| Gleason score               |             |          |          | 0.441   |
| ≤6                          | 59 (26.6)   | 24 (21.6) | 35 (26.6) |         |
| 7                           | 145 (65.3)  | 78 (70.3) | 67 (65.3) |         |
| 8                           | 8 (3.6)     | 4 (3.6)  | 4 (3.6)  |         |
| 9                           | 10 (4.5)    | 5 (4.5)  | 5 (4.5)  |         |
| T-stage                     |             |          |          | 0.717   |
| T2a                         | 28 (12.6)   | 14 (12.6) | 14 (12.6) |         |
| T2b                         | 38 (17.1)   | 19 (17.1) | 19 (17.1) |         |
| T2c                         | 119 (53.6)  | 56 (50.5) | 63 (56.8) |         |
| T3a                         | 21 (9.5)    | 13 (11.7) | 8 (7.2)   |         |
| T3b                         | 16 (7.2)    | 9 (8.1)  | 7 (6.3)  |         |
| N-stage                     |             |          |          | 0.155   |
| 0                           | 267 (97.1)  | 111 (100)| 109 (98.2)|         |

BMI: body mass index; pre-op PSA: pre-operative prostate-specific antigen; RRP: radical retropubic prostatectomy; LRP: laparoscopic radical prostatectomy; RARP: robot-assisted radical prostatectomy; BCR: biochemical recurrence.
### Comparison of clinical and pathological parameters according to BMI

As shown in Table 2, there was no significant difference in clinical and pathological parameters according to BMI ($p > 0.05$).
Table 2  
Comparison of clinical and pathological parameters according to body mass index

| Parameter                      | ≤ Normal | Overweight | Obese     | p-value |
|-------------------------------|----------|------------|-----------|---------|
| Number                        | 63       | 73         | 86        |         |
| Age (years)                   | 68.57 ± 6.06 | 68.07 ± 6.85 | 67.07 ± 5.76 | 0.321  |
| IOM (mm$^2$/cm$^2$)           | 10.84 ± 2.18 | 11.13 ± 2.02 | 11.59 ± 2.37 | 0.115  |
| BMI (kg/m$^2$)                | 21.11 ± 1.45 | 24.06 ± 0.51 | 27.25 ± 1.79 | < 0.001|
| Pre-op PSA (ng/mL)            | 13.97 ± 17.97 | 11.01 ± 10.93 | 10.40 ± 10.57 | 0.237  |
| Prostate volume (cc)          | 32.54 ± 12.95 | 33.01 ± 14.39 | 37.54 ± 14.42 | 0.062  |
| Type of operation             |          |            |           | 0.291  |
| RRP                           | 48 (76.2) | 58 (79.5)  | 57 (66.3) |         |
| LRP                           | 0 (0.0)   | 0 (0.0)    | 1 (1.2)   |         |
| RARP                          | 15 (23.8) | 15 (20.5)  | 28 (32.6) |         |
| Gleason score                 |          |            |           | 0.165  |
| ≤6                            | 14 (22.2) | 20 (27.4)  | 25 (29.1) |         |
| 7                             | 43 (68.3) | 49 (67.1)  | 53 (61.6) |         |
| 8                             | 5 (7.9)   | 1 (1.4)    | 2 (2.3)   |         |
| 9                             | 1 (1.6)   | 3 (4.1)    | 6 (7.0)   |         |
| T-stage                       |          |            |           | 0.220  |
| T2a                           | 7 (11.1)  | 14 (19.2)  | 7 (8.1)   |         |
| T2b                           | 7 (11.1)  | 13 (17.8)  | 18 (20.9) |         |
| T2c                           | 37 (58.7) | 37 (50.7)  | 45 (52.3) |         |
| T3a                           | 5 (7.9)   | 5 (6.8)    | 11 (12.8) |         |
| T3b                           | 7 (11.1)  | 4 (5.5)    | 5 (5.8)   |         |
| N-stage                       |          |            |           | 0.524  |
| 0                             | 62 (98.4) | 72 (98.6)  | 86 (100)  |         |
| 1                             | 1 (1.6)   | 1 (1.4)    | 0 (0.0)   |         |

IOM: Internal obturator muscle mass index; BMI: body mass index; pre-op PSA: pre-operative prostate-specific antigen; RRP: radical retropubic prostatectomy; LRP: laparoscopic radical prostatectomy; RARP: robot-assisted radical prostatectomy; BCR: biochemical recurrence
| Parameter | ≤ Normal   | Overweight | Obese      | p-value |
|-----------|------------|------------|------------|---------|
| cM stage  |            |            |            | 0.282   |
| 0         | 62 (98.4)  | 73 (100)   | 86 (100.0) |         |
| 1         | 1 (1.6)    | 0 (0.0)    | 0 (0.0)    |         |
| BCR       |            |            |            | 0.521   |
| 0         | 46 (73.0)  | 59 (80.8)  | 68 (79.1)  |         |
| 1         | 17 (27.0)  | 14 (19.2)  | 18 (20.9)  |         |

IOM: Internal obturator muscle mass index; BMI: body mass index; pre-op PSA: pre-operative prostate-specific antigen; RRP: radical retropubic prostatectomy; LRP: laparoscopic radical prostatectomy; RARP: robot-assisted radical prostatectomy; BCR: biochemical recurrence

**Cox proportional hazards model analysis of biochemical recurrence**

Age, pre-op PSA, ECE, and T-stage was associated with BCR (p = 0.049, p < 0.001, p = 0.001, p = 0.004, respectively). However, there was no association between BCR and BMI, prostate volume, Gleason score, resection margin, N-stage, or M-stage (p > 0.05; Table 3). In particular, IOM mass index was not associated with BCR (p > 0.05; Fig. 2).
| Parameter                                      | HR  | 95% CI          | p-value |
|-----------------------------------------------|-----|-----------------|---------|
| Age (years)                                   | 0.945 | 0.892–1.000 | 0.049   |
| IOM (mm²/cm²) (low vs. high)                  | 0.891 | 0.462–1.719 | 0.731   |
| BMI (kg/m²)                                   |     | 0.142          |         |
| ≤ Normal                                       | -    |                |         |
| Overweight                                    | 0.880 | 0.379–2.042 |         |
| Obesity                                       | 0.455 | 0.195–1.063 |         |
| Pre-op PSA (ng/ml)                            | 1.064 | 1.045–1.083 | < 0.001 |
| Prostate volume (cc)                          | 1.016 | 0.990–1.042 | 0.226   |
| Gleason score                                 |     | 0.364          |         |
| ≤6                                            | -    |                |         |
| 7                                             | 1.263 | 0.478–3.340 |         |
| 8                                             | 1.473 | 0.317–6.844 |         |
| 9                                             | 3.064 | 0.798–11.760 |         |
| ECE (No vs. Yes)                              | 5.551 | 2.011–15.322 | 0.001   |
| Resection margin (- vs. +)                    | 1.040 | 0.479–2.262 | 0.920   |
| T-stage                                       | 0.004 |                |         |
| T2a                                           | -    |                |         |
| T2b                                           | 13.260 | 2.218–79.262 |         |
| T2c                                           | 3.157 | 0.609–16.373 |         |
| T3a                                           | 1.564 | 0.177–13.785 |         |
| T3b                                           | 4.830 | 0.700–33.326 |         |
| N-stage (no involvement vs. LN involvement)   | 0.300 | 0.028–3.202 | 0.319   |
| M-stage (no meta vs. meta)                    | 0.000 | 0.000–         | 0.985   |

IOM: internal obturator muscle mass index; BMI: body mass index; pre-op PSA: pre-operative prostate-specific antigen; ECE: extracapsular extension; LN: lymph node.

**Discussion**
The results of the present study suggest that IOM mass index is not associated with BCR after RP in Korean men. The present study is the first to show no significant association between IOM mass index and BCR in men with RP. Thus, IOM mass index may not be a prognostic marker for BCR in Korean men with localized PCa undergoing RP.

Previous studies suggest that high BMI is associated with increased risk of PCa. A meta-analysis by Bergstrom et al. reports a 6% increase in the risk of PCa in overweight men and a 12% increase in obese men compared with men of normal weight. MacInnis et al. reported a weak positive association between BMI and risk of PCa; BMI was associated with moderate increase in the risk of advanced PCa. The relationship between BMI and BCR after RP remains controversial. Freedland et al. reported that obesity among men treated with RP was associated with high-grade tumors, a trend toward increased risk of a positive surgical margin, and high BCR. Magheli et al. reported that high BMI is associated with adverse pathological findings and is a strong independent predictor of BCR after RP. Asmar et al. reported that both obesity and hypertension are associated with an increased risk of BCR after RP, independent of age at the time of diagnosis or tumor pathological features. By contrast, Tomaszewski et al. reported that obesity is not associated with adverse pathologic features, positive surgical margin, or BCR. They suggested that their data provide evidence that obese men undergoing RP are not more likely to suffer PCa progression. In addition, Siddiqui et al. reported that obese patients appeared to have worse pathologic features at the time of prostatectomy; however, BMI did not appear to be an independent predictor of recurrence or survival after prostatectomy. The present study found no association between BMI and BCR. Therefore, we believe that the relationship between BMI and BCR after RP remains unclear.

Sarcopenia is a process associated with normal aging; however, it is exacerbated by the hypercatabolic state and inflammatory responses caused by malignancy. A systematic review by Joglekar et al. investigated the impact of sarcopenia on outcome following surgical resection of cancer and reported that sarcopenia is an independent prognostic factor for both complications and survival following surgical resection. Sarcopenia is a more objective and comprehensive pre-operative risk factor that predicts all-cause survival for bladder cancer after radical cystectomy (RC). With respect to PCa, several reports link sarcopenia and survival. Thus, sarcopenia could be used to predict non-cancer-related death in men with PCa after RT and may be a poor prognostic factor for CRPC treated with chemotherapy. However, the association between sarcopenia and survival after RP is very unclear. Long-term follow-up studies are necessary to identify (or not) any association between sarcopenia or IOM mass index and survival.

We recognize that this study has several limitations. First, we only measured internal obturator muscle mass, but not SMI. In general, SMI was defined as the cross-sectional area of the rectus abdominis; internal, external, and transverse obliques; psoas; quadratus lumborum; and erector spinae muscles from L3 down. However, because this was a multi-institutional study, different authors have different protocols.
for pre-operative CT and MRI. Therefore, we selected only the internal obturator muscle area in the pelvis in the MRI, because of internal obturator muscle is the only measurable muscle in the pelvis MRI axial cut. So, we couldn't compared IOM mass with general SMI. Second, many patients who underwent RP at these institutions were excluded from the analysis due to differences in CT or MRI protocols. In some institutions, radiologists were not able to measure the internal obturator muscle at the same levels. Third, the follow-up period was too short to get an accurate picture of survival. In this case we did not examine cancer-specific or overall survival; studies may need follow-up data spanning more than 15 years to get an accurate picture of the association between IOM mass index and the survival of PCa patients.

**Conclusions**

Pre-operative IOM mass index was not associated with BCR; however, long-term (>15 years) follow-up is necessary to better answer this still controversial question.

**Declarations**

**Conflicts of interest**

The authors declare no competing interests.

**Acknowledgements**

This study was supported by research fund from The Hannam Urological Association, 2018 and the International Science and Business Belt Program funded by the Ministry of Science, ICT & Future Planning (2017K000490).

**References**

1. Center M, Jemal A, Lortet Tieulent J, Ward E, Ferlay J, Brawley O, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012;61:1079-92

2. Lee HY, Park S, Doo SW, Yang WJ, Song YS, Kim JH. Trends in Prostate Cancer Prevalence and Radical Prostatectomy Rate according to Age Structural Changes in South Korea between 2005 and 2015. Yonsei Med J 2019;60:257-66

3. Cruz Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing 2010;39:412-23

4. Prado CM, Baracos VE, McCargar LJ, Reiman T, Mourtzakis M, Tonkin K, et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 2009;15:2920-6
5. Miyamoto Y, Baba Y, Sakamoto Y, Ohuchi M, Tokunaga R, Kurashige J, et al. Sarcopenia is a Negative Prognostic Factor After Curative Resection of Colorectal Cancer. Ann Surg Oncol 2015;22:2663-8
6. Harimoto N, Shirabe K, Yamashita YI, Ikegami T, Yoshizumi T, Soejima Y, et al. Sarcopenia as a predictor of prognosis in patients following hepatectomy for hepatocellular carcinoma. Br J Surg 2013;100:1523-30
7. Peng P, Hyder O, Firoozmand A, Kneuertz P, Schulick RD, Huang D, et al. Impact of sarcopenia on outcomes following resection of pancreatic adenocarcinoma. J Gastrointest Surg 2012;16:1478-86
8. Smith AB, Deal AM, Yu H, Boyd B, Matthews J, Wallen EM, et al. Sarcopenia as a predictor of complications and survival following radical cystectomy. J Urol 2014;191:1714-20
9. Psutka SP, Carrasco A, Schmit GD, Moynagh MR, Boorjian SA, Frank I, et al. Sarcopenia in patients with bladder cancer undergoing radical cystectomy: impact on cancer-specific and all-cause mortality. Cancer 2014;120:2910-8
10. Psutka SP, Boorjian SA, Moynagh MR, Schmit GD, Frank I, Carrasco A, et al. Mortality after radical cystectomy: impact of obesity versus adiposity after adjusting for skeletal muscle wasting. J Urol 2015;193:1507-13
11. Psutka SP, Boorjian SA, Moynagh MR, Schmit GD, Costello BA, Thompson RH, et al. Decreased Skeletal Muscle Mass is Associated with an Increased Risk of Mortality after Radical Nephrectomy for Localized Renal Cell Cancer. J Urol 2016;195:270-6
12. McDonald AM, Swain TA, Mayhew DL, Cardan RA, Baker CB, Harris DM, et al. CT Measures of Bone Mineral Density and Muscle Mass Can Be Used to Predict Noncancer Death in Men with Prostate Cancer. Radiology 2017;282:475-83
13. Mason RJ, Boorjian SA, Bhindi B, Rangel L, Frank I, Karnes RJ, et al. The Association Between Sarcopenia and Oncologic Outcomes After Radical Prostatectomy. Clin Genitourin Cancer 2018;16:e629-e36
14. Kim MK, Lee WY, Kang JH, Kim BT, Kim SM, Kim EM, et al. 2014 clinical practice guidelines for overweight and obesity in Korea. Endocrinol Metab 2014;29:405-9
15. MacInnis RJ, English DR. Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. Cancer Causes Control 2006;17:989-1003
16. Bergström A, Pisani P, Tenet V, Wolk A, Adami HO. Overweight as an avoidable cause of cancer in Europe. Int J Cancer 2001;91:421-30
17. Freedland SJ, Aronson WJ, Kane CJ, Presti JC, Amling CL, Elashoff D, et al. Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group. J Clin Oncol 2004;22:446-53
18. Magheli A, Rais Bahrami S, Trock BJ, Humphreys EB, Partin AW, Han M, et al. Impact of body mass index on biochemical recurrence rates after radical prostatectomy: an analysis utilizing propensity score matching. Urology (Ridgewood, N.J.) 2008;72:1246-51
19. Asmar R, Beebe Dimmer JL, Korgavkar K, Keele GR, Cooney KA. Hypertension, obesity and prostate cancer biochemical recurrence after radical prostatectomy. Prostate Cancer Prostatic Dis 2013;16:62-6

20. Tomaszewski J, Chen Y, Bertolet M, Ristau BT, Woldemichael E, Nelson JB. Obesity is not associated with aggressive pathologic features or biochemical recurrence after radical prostatectomy. Urology (Ridgewood, N.J.) 2013;81:992-6

21. Siddiqui SA, Inman BA, Sengupta S, Slezak JM, Bergstralh EJ, Leibovich BC, et al. Obesity and survival after radical prostatectomy: A 10-year prospective cohort study. Cancer 2006;107:521-9

22. Prado CM, Wells JC, Smith SR, Stephan BC, Siervo M. Sarcopenic obesity: A Critical appraisal of the current evidence. Clin Nutr (Edinburgh) 2012;31:583-601

23. Joglekar S, Nau PN, Mezhir J. The impact of sarcopenia on survival and complications in surgical oncology: A review of the current literature. J Surg Oncol 2015;112:503-9

24. Hirasawa Y, Nakashima J, Yunaiyama D, Sugihara T, Gondo T, Nakagami Y, et al. Sarcopenia as a Novel Preoperative Prognostic Predictor for Survival in Patients with Bladder Cancer Undergoing Radical Cystectomy. Ann Surg Oncol 2016;23:1048-54

25. Ohtaka A, Aoki H, Nagata M, Kanayama M, Shimizu F, Ide H, et al. Sarcopenia is a poor prognostic factor of castration-resistant prostate cancer treated with docetaxel therapy. Prostate Int 2019;7:9-14